CA2713025C - Kappa selective opioid receptor antagonist - Google Patents

Kappa selective opioid receptor antagonist Download PDF

Info

Publication number
CA2713025C
CA2713025C CA2713025A CA2713025A CA2713025C CA 2713025 C CA2713025 C CA 2713025C CA 2713025 A CA2713025 A CA 2713025A CA 2713025 A CA2713025 A CA 2713025A CA 2713025 C CA2713025 C CA 2713025C
Authority
CA
Canada
Prior art keywords
disorder
ethanol
pharmaceutically acceptable
compound
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2713025A
Other languages
English (en)
French (fr)
Other versions
CA2713025A1 (en
Inventor
Nuria Diaz Buezo
David Lee Mckinzie
Charles Howard Mitch
Concepcion Pedregal-Tercero
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CA2713025A1 publication Critical patent/CA2713025A1/en
Application granted granted Critical
Publication of CA2713025C publication Critical patent/CA2713025C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2713025A 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist Active CA2713025C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08380012 2008-01-22
EP08380012.8 2008-01-22
US3912108P 2008-03-25 2008-03-25
US61/039,121 2008-03-25
PCT/US2009/030811 WO2009094260A1 (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Publications (2)

Publication Number Publication Date
CA2713025A1 CA2713025A1 (en) 2009-07-30
CA2713025C true CA2713025C (en) 2012-12-04

Family

ID=40876972

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2713025A Active CA2713025C (en) 2008-01-22 2009-01-13 Kappa selective opioid receptor antagonist

Country Status (32)

Country Link
US (2) US7709522B2 (https=)
EP (1) EP2252581B1 (https=)
JP (1) JP5345637B2 (https=)
KR (1) KR101172170B1 (https=)
CN (1) CN101925576B (https=)
AR (1) AR070158A1 (https=)
AU (1) AU2009206653B2 (https=)
BR (1) BRPI0907382B8 (https=)
CA (1) CA2713025C (https=)
CO (1) CO6290644A2 (https=)
CY (1) CY1113071T1 (https=)
DK (1) DK2252581T3 (https=)
DO (1) DOP2010000222A (https=)
EA (1) EA017484B1 (https=)
EC (1) ECSP10010365A (https=)
ES (1) ES2388708T3 (https=)
HR (1) HRP20120558T1 (https=)
IL (1) IL206038A (https=)
JO (1) JO2797B1 (https=)
MA (1) MA32751B1 (https=)
MX (1) MX2010007849A (https=)
MY (1) MY163014A (https=)
NZ (1) NZ586225A (https=)
PE (1) PE20091317A1 (https=)
PL (1) PL2252581T3 (https=)
PT (1) PT2252581E (https=)
SI (1) SI2252581T1 (https=)
TN (1) TN2010000306A1 (https=)
TW (1) TWI422369B (https=)
UA (1) UA100715C2 (https=)
WO (1) WO2009094260A1 (https=)
ZA (1) ZA201003908B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091439A1 (es) * 2008-01-22 2009-10-19 Takeda Pharmaceutical Compuestos triciclicos como antagonistas de crf
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
EP2757881A4 (en) 2011-09-15 2014-11-12 Univ Kansas KAPPA OPIATE RECEPTOR EFFECTORS AND USES THEREOF
WO2013042054A1 (en) 2011-09-19 2013-03-28 Carmel - Haifa University Economic Corporation Ltd. Buprenorphine for the treatment of acute suicidality
EP2773352B1 (en) 2011-12-09 2017-06-28 Research Triangle Institute 1-substituted 4-arylpiperazine as kappa opioid receptor antagonists
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9283196B1 (en) 2013-01-30 2016-03-15 MediSynergics, LLC Cycloalkyl-diamines for CNS disorders
CA2911231C (en) * 2013-05-24 2021-12-07 Alkermes Pharma Ireland Limited Morphan and morphinan analogues, and methods of use
US10316021B2 (en) * 2016-11-28 2019-06-11 Pfizer Inc. Heteroarylphenoxy benzamide kappa opioid ligands
ES2926533T3 (es) 2017-03-17 2022-10-26 Scripps Research Inst Antagonistas del receptor opioideo kappa y productos y métodos relacionados con los mismos
JP6480616B1 (ja) 2018-02-08 2019-03-13 有限会社 ディオン光学技研 照準スコープ
US11266627B1 (en) 2021-05-04 2022-03-08 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
CN114195693A (zh) * 2020-09-17 2022-03-18 广东东阳光药业有限公司 一种酰胺化合物的晶型及其制备方法
CN114591211B (zh) * 2020-12-04 2025-10-21 广东东阳光药业股份有限公司 一种酰胺化合物的共晶及其制备方法
US12161622B2 (en) 2021-05-04 2024-12-10 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
AU2022268720A1 (en) 2021-05-04 2023-12-21 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
JP2025503646A (ja) * 2022-01-10 2025-02-04 ヤンセン ファーマシューティカルズ，インコーポレーテッド うつ病の治療のための組成物及び方法
EP4463143A1 (en) * 2022-01-10 2024-11-20 Janssen Pharmaceuticals, Inc. Compositions and methods for the treatment of depression
EP4489730B1 (en) 2022-03-07 2026-01-21 Janssen Pharmaceuticals, Inc. Compositions comprising aticaprant
WO2023170547A1 (en) * 2022-03-07 2023-09-14 Janssen Pharmaceuticals, Inc. Pure forms of crystalline aticaprant
CN119156211A (zh) 2022-03-07 2024-12-17 杨森制药公司 用于治疗重性抑郁障碍的多晶型形式的阿替卡普兰
JP7176142B1 (ja) 2022-03-09 2022-11-21 直迪 清瀬 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5457208A (en) * 1993-06-21 1995-10-10 Regents Of The University Of Minnesota Kappa opioid receptor antagonists
WO2000069858A1 (en) * 1999-05-12 2000-11-23 F. Hoffmann-La Roche Ag Imidazodiazepine derivative
JP2004510789A (ja) * 2000-10-05 2004-04-08 モーラー，ハンス 選択的抗不安治療薬
JP2004518654A (ja) * 2000-12-21 2004-06-24 ザ マクレーン ホスピタル コーポレーション 鬱病の治療法
US6974824B2 (en) 2001-01-08 2005-12-13 Research Triangle Institute Kappa opioid receptor ligands
DE60319812T2 (de) * 2002-03-28 2009-04-23 Wisys Technology Foundation, Inc., Madison Angstlösende wirkstoffe mit verminderten beruhigenden und ataktischen nebenwirkungen
KR101025633B1 (ko) * 2002-09-19 2011-03-30 일라이 릴리 앤드 캄파니 오피오이드 수용체 안타고니스트로서의 디아릴 에테르
CN1756746A (zh) * 2003-03-07 2006-04-05 伊莱利利公司 作为阿片样物质受体拮抗剂的6－取代的烟酰胺衍生物
US7396943B2 (en) * 2003-03-07 2008-07-08 Eli Lilly And Company Opioid receptor antagonists
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
CN1894240A (zh) * 2003-12-22 2007-01-10 伊莱利利公司 阿片受体拮抗剂
AU2005222640A1 (en) * 2004-03-12 2005-09-29 The Mclean Hospital Corporation Salvinorin derivatives and uses thereof
EP1727788B1 (en) * 2004-03-12 2010-07-28 Eli Lilly And Company Opioid receptor antagonists
EP1730140B1 (en) * 2004-03-12 2008-06-25 Eli Lilly And Company Opioid receptor antagonists
JP2007529523A (ja) * 2004-03-15 2007-10-25 イーライ リリー アンド カンパニー 肥満症を治療するためのオピオイド受容体拮抗物質としての４−（５−アミノメチル）−インドール−１−イルメチル）−ベンズアミド誘導体および関連化合物
CA2557794A1 (en) * 2004-03-15 2005-10-06 Eli Lilly And Company Opioid receptor antagonists
US8551986B2 (en) * 2005-12-08 2013-10-08 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
DK2001456T3 (da) 2006-04-04 2010-04-12 Emodys Gmbh Anvendelse af kappa-opiodreceptorantagonistholde sammensætninger til behandling af dissociative forstyrrelser
WO2008021849A2 (en) 2006-08-09 2008-02-21 Smithkline Beecham Corporation Novel compounds as antagonists or inverse agonists at opioid receptors
US20100222345A1 (en) 2006-08-09 2010-09-02 Caroline Jean Diaz Novel compounds as antagonists or inverse agonists for opioid receptors
CN101511808A (zh) 2006-09-08 2009-08-19 辉瑞产品公司 二芳基醚衍生物及其用途
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist

Also Published As

Publication number Publication date
PE20091317A1 (es) 2009-09-03
DK2252581T3 (da) 2012-07-16
US20100197669A1 (en) 2010-08-05
JP2011524850A (ja) 2011-09-08
BRPI0907382B8 (pt) 2021-05-25
CN101925576B (zh) 2013-02-06
ECSP10010365A (es) 2010-08-31
PL2252581T3 (pl) 2012-10-31
KR101172170B1 (ko) 2012-08-07
AU2009206653B2 (en) 2013-07-18
EA017484B1 (ru) 2012-12-28
BRPI0907382B1 (pt) 2020-03-10
US8173695B2 (en) 2012-05-08
UA100715C2 (ru) 2013-01-25
HK1146822A1 (en) 2011-07-15
WO2009094260A1 (en) 2009-07-30
SI2252581T1 (sl) 2012-09-28
DOP2010000222A (es) 2015-11-15
MA32751B1 (fr) 2011-11-01
NZ586225A (en) 2012-05-25
MY163014A (en) 2017-07-31
BRPI0907382A2 (pt) 2015-07-21
AR070158A1 (es) 2010-03-17
TN2010000306A1 (en) 2011-11-11
US20090186873A1 (en) 2009-07-23
KR20100095639A (ko) 2010-08-31
MX2010007849A (es) 2010-08-09
ZA201003908B (en) 2011-11-30
ES2388708T3 (es) 2012-10-17
JO2797B1 (en) 2014-03-15
CA2713025A1 (en) 2009-07-30
EP2252581B1 (en) 2012-06-20
JP5345637B2 (ja) 2013-11-20
PT2252581E (pt) 2012-08-31
EA201070877A1 (ru) 2010-12-30
CO6290644A2 (es) 2011-06-20
TW200936129A (en) 2009-09-01
IL206038A0 (en) 2010-11-30
HRP20120558T1 (hr) 2012-10-31
AU2009206653A1 (en) 2009-07-30
EP2252581A1 (en) 2010-11-24
CY1113071T1 (el) 2016-04-13
IL206038A (en) 2013-11-28
TWI422369B (zh) 2014-01-11
US7709522B2 (en) 2010-05-04
CN101925576A (zh) 2010-12-22

Similar Documents

Publication Publication Date Title
CA2713025C (en) Kappa selective opioid receptor antagonist
CA2946153C (en) Use of known compounds as d-amino acid oxidase inhibitors
RS59845B1 (sr) Jedinjenja azetidiniloksifenilpirolidina
ES2675791T3 (es) Compuesto 3-fenoximetilpirrolidina
JP2010526075A (ja) （−）−ｅ−１０−ｏｈ−ｎｔの組成物、ならびにそれらの合成および使用のための方法
HK1146822B (en) Kappa selective opioid receptor antagonist
CA2715192A1 (en) Beloxepin, its enantiomers, and analogs thereof for the treatment of pain
JP2011512414A5 (https=)
Gerspacher et al. N-[(R, R)-(E)-1-(4-chloro-benzyl)-3-(2-oxo-azepan-3-ylcarbamoyl)-allyl]-N-methyl-3, 5-bis-trifluoromethyl-benzamide: an orally active neurokinin NK1/NK2 antagonist
Paliwal et al. Discovery of a novel, potent and orally active series of γ-lactams as selective NK1 antagonists
RS108904A (sr) N,n-disupstituisani diazocikloalkani korisni za tretman poremećaja cns usled serotonergijske disfunkcije
WO2022187206A1 (en) Dual-target mu opioid and dopamine d3 receptors ligands; preparation and use thereof
CA2846200A1 (en) Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound
Lorthiois et al. trans-(3S, 4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: Prime site exploration using an amino linker

Legal Events

Date Code Title Description
EEER Examination request
MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241120

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241120

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202